The prognostic impact of prior low grade histology in patients with anaplastic gliomas: A case-control study

Edward Dropcho, Seng Jaw Soong

Research output: Contribution to journalArticle

64 Citations (Scopus)

Abstract

At the time of recurrence, the majority of low grade cerebral gliomas transform to a higher grade of histologic malignancy. The purpose of this study was to determine the survival outcome for patients whose anaplastic gliomas began as low-grade tumors compared with patients with de novo high- grade gliomas. Seventy-seven (11.5%) of 667 patients with anaplastic gliomas consecutively treated at the University of Alabama at Birmingham had histologically proven prior low-grade tumors. As a group, the patients with prior low-grade tumors would be expected to have a relatively favorable outcome, as they were younger and had a lower proportion of glioblastoma multiforme than the patients with de novo anaplastic gliomas. To provide a valid comparison, we performed a matched case-control study. We matched 68 patients from the prior low-grade group one-to-one with patients from the de hove group for tumor histology, age, Karnofsky performance scores, and type of surgery, without knowledge of outcome. The two groups received comparable radiotherapy and chemotherapy. For the 68 patients with prior low-grade tumor, median actuarial survival from the time of diagnosis of malignant degeneration was 19.7 months and the 5-year survival rate was 22%, compared with 22.0 months and 28% for the 68 matched de novo patients. Kaplan-Meier survival curves for the two groups did not significantly differ (p = 0.24 by logrank test). There were no significant survival differences between the patient subsets of prior low-grade versus de hove with glioblastoma, anaplastic astrocytoma, or anaplastic oligodendroglioma/mixed anaplastic glioma. These data indicate that with currently available treatment options, the survival outlook for patients with anaplastic gliomas, whose tumors arose from transformation of low-grade gliomas, is equivalent to the prognosis for patients with de hove anaplastic gliomas.

Original languageEnglish
Pages (from-to)684-690
Number of pages7
JournalNeurology
Volume47
Issue number3
StatePublished - Sep 1996

Fingerprint

Glioma
Case-Control Studies
Histology
Neoplasms
Survival
Glioblastoma
Oligodendroglioma
Astrocytoma
Kaplan-Meier Estimate
Radiotherapy
Survival Rate
Recurrence
Drug Therapy

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

The prognostic impact of prior low grade histology in patients with anaplastic gliomas : A case-control study. / Dropcho, Edward; Soong, Seng Jaw.

In: Neurology, Vol. 47, No. 3, 09.1996, p. 684-690.

Research output: Contribution to journalArticle

@article{ed789d6678724b5db8117f1069aff7f0,
title = "The prognostic impact of prior low grade histology in patients with anaplastic gliomas: A case-control study",
abstract = "At the time of recurrence, the majority of low grade cerebral gliomas transform to a higher grade of histologic malignancy. The purpose of this study was to determine the survival outcome for patients whose anaplastic gliomas began as low-grade tumors compared with patients with de novo high- grade gliomas. Seventy-seven (11.5{\%}) of 667 patients with anaplastic gliomas consecutively treated at the University of Alabama at Birmingham had histologically proven prior low-grade tumors. As a group, the patients with prior low-grade tumors would be expected to have a relatively favorable outcome, as they were younger and had a lower proportion of glioblastoma multiforme than the patients with de novo anaplastic gliomas. To provide a valid comparison, we performed a matched case-control study. We matched 68 patients from the prior low-grade group one-to-one with patients from the de hove group for tumor histology, age, Karnofsky performance scores, and type of surgery, without knowledge of outcome. The two groups received comparable radiotherapy and chemotherapy. For the 68 patients with prior low-grade tumor, median actuarial survival from the time of diagnosis of malignant degeneration was 19.7 months and the 5-year survival rate was 22{\%}, compared with 22.0 months and 28{\%} for the 68 matched de novo patients. Kaplan-Meier survival curves for the two groups did not significantly differ (p = 0.24 by logrank test). There were no significant survival differences between the patient subsets of prior low-grade versus de hove with glioblastoma, anaplastic astrocytoma, or anaplastic oligodendroglioma/mixed anaplastic glioma. These data indicate that with currently available treatment options, the survival outlook for patients with anaplastic gliomas, whose tumors arose from transformation of low-grade gliomas, is equivalent to the prognosis for patients with de hove anaplastic gliomas.",
author = "Edward Dropcho and Soong, {Seng Jaw}",
year = "1996",
month = "9",
language = "English",
volume = "47",
pages = "684--690",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - The prognostic impact of prior low grade histology in patients with anaplastic gliomas

T2 - A case-control study

AU - Dropcho, Edward

AU - Soong, Seng Jaw

PY - 1996/9

Y1 - 1996/9

N2 - At the time of recurrence, the majority of low grade cerebral gliomas transform to a higher grade of histologic malignancy. The purpose of this study was to determine the survival outcome for patients whose anaplastic gliomas began as low-grade tumors compared with patients with de novo high- grade gliomas. Seventy-seven (11.5%) of 667 patients with anaplastic gliomas consecutively treated at the University of Alabama at Birmingham had histologically proven prior low-grade tumors. As a group, the patients with prior low-grade tumors would be expected to have a relatively favorable outcome, as they were younger and had a lower proportion of glioblastoma multiforme than the patients with de novo anaplastic gliomas. To provide a valid comparison, we performed a matched case-control study. We matched 68 patients from the prior low-grade group one-to-one with patients from the de hove group for tumor histology, age, Karnofsky performance scores, and type of surgery, without knowledge of outcome. The two groups received comparable radiotherapy and chemotherapy. For the 68 patients with prior low-grade tumor, median actuarial survival from the time of diagnosis of malignant degeneration was 19.7 months and the 5-year survival rate was 22%, compared with 22.0 months and 28% for the 68 matched de novo patients. Kaplan-Meier survival curves for the two groups did not significantly differ (p = 0.24 by logrank test). There were no significant survival differences between the patient subsets of prior low-grade versus de hove with glioblastoma, anaplastic astrocytoma, or anaplastic oligodendroglioma/mixed anaplastic glioma. These data indicate that with currently available treatment options, the survival outlook for patients with anaplastic gliomas, whose tumors arose from transformation of low-grade gliomas, is equivalent to the prognosis for patients with de hove anaplastic gliomas.

AB - At the time of recurrence, the majority of low grade cerebral gliomas transform to a higher grade of histologic malignancy. The purpose of this study was to determine the survival outcome for patients whose anaplastic gliomas began as low-grade tumors compared with patients with de novo high- grade gliomas. Seventy-seven (11.5%) of 667 patients with anaplastic gliomas consecutively treated at the University of Alabama at Birmingham had histologically proven prior low-grade tumors. As a group, the patients with prior low-grade tumors would be expected to have a relatively favorable outcome, as they were younger and had a lower proportion of glioblastoma multiforme than the patients with de novo anaplastic gliomas. To provide a valid comparison, we performed a matched case-control study. We matched 68 patients from the prior low-grade group one-to-one with patients from the de hove group for tumor histology, age, Karnofsky performance scores, and type of surgery, without knowledge of outcome. The two groups received comparable radiotherapy and chemotherapy. For the 68 patients with prior low-grade tumor, median actuarial survival from the time of diagnosis of malignant degeneration was 19.7 months and the 5-year survival rate was 22%, compared with 22.0 months and 28% for the 68 matched de novo patients. Kaplan-Meier survival curves for the two groups did not significantly differ (p = 0.24 by logrank test). There were no significant survival differences between the patient subsets of prior low-grade versus de hove with glioblastoma, anaplastic astrocytoma, or anaplastic oligodendroglioma/mixed anaplastic glioma. These data indicate that with currently available treatment options, the survival outlook for patients with anaplastic gliomas, whose tumors arose from transformation of low-grade gliomas, is equivalent to the prognosis for patients with de hove anaplastic gliomas.

UR - http://www.scopus.com/inward/record.url?scp=0029843049&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029843049&partnerID=8YFLogxK

M3 - Article

C2 - 8797465

AN - SCOPUS:0029843049

VL - 47

SP - 684

EP - 690

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 3

ER -